Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02942004
Registration number
NCT02942004
Ethics application status
Date submitted
20/10/2016
Date registered
21/10/2016
Date last updated
28/01/2022
Titles & IDs
Public title
A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)
Query!
Scientific title
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression
Query!
Secondary ID [1]
0
0
547-PPD-202 B
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Postpartum Depression
0
0
Query!
Condition category
Condition code
Mental Health
0
0
0
0
Query!
Depression
Query!
Reproductive Health and Childbirth
0
0
0
0
Query!
Childbirth and postnatal care
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - SAGE-547 60 µg/kg/h
Treatment: Drugs - SAGE-547 90 µg/kg/h
Placebo Comparator: Placebo - Participants received infusion rates equivalent to either the 60 micrograms per kilogram per hour (µg/kg/h) or 90 µg/kg/h group.
Experimental: SAGE-547 60 µg/kg/h - Participants received a 4-hour titration period of 30 µg/kg/h (0 to 4 hours), then 60 µg/kg/h (4 to 56 hours), followed by a taper to 30 µg/kg/h (56 to 60 hours).
Experimental: SAGE-547 90 µg/kg/h - Participants received a 4-hour dose titration period of 30 µg/kg/h (0 to 4 hours), then 60 µg/kg/h (4 to 24 hours), then 90 µg/kg/h (24 to 52 hours), followed by a taper to 60 µg/kg/h (52 to 56 hours), and 30 µg/kg/h (56 to 60 hours).
Treatment: Drugs: Placebo
Intravenous infusion of matching placebo for either SAGE-547 60 µg/kg/h or 90 µg/kg/h.
Treatment: Drugs: SAGE-547 60 µg/kg/h
Intravenous infusion of SAGE-547.
Treatment: Drugs: SAGE-547 90 µg/kg/h
Intravenous infusion of SAGE-547.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change From Baseline at 60 Hours in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score
Query!
Assessment method [1]
0
0
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Query!
Timepoint [1]
0
0
Baseline, Hour 60
Query!
Secondary outcome [1]
0
0
Change From Baseline in HAM-D Total Score at Day 30
Query!
Assessment method [1]
0
0
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Query!
Timepoint [1]
0
0
Baseline, Day 30
Query!
Secondary outcome [2]
0
0
Change From Baseline in HAM-D Total Score
Query!
Assessment method [2]
0
0
The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Query!
Timepoint [2]
0
0
Baseline, Hours 2, 4, 8, 12, 24, 36, 48, 72, and Days 7, 14, and 21
Query!
Secondary outcome [3]
0
0
Percentage of Participants With HAM-D Response
Query!
Assessment method [3]
0
0
The HAM-D response is defined as having a 50% or greater reduction from baseline in HAM-D total score. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Query!
Timepoint [3]
0
0
Hour 60, Days 7 and 30
Query!
Secondary outcome [4]
0
0
Percentage of Participants With HAM-D Remission
Query!
Assessment method [4]
0
0
The HAM-D remission is defined as having a HAM-D total score of =7. The HAM-D Total Score comprises a sum of the 17 individual item scores. Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. The Total Score can range from 0 to 52, and higher scores indicate a greater degree of depression. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Query!
Timepoint [4]
0
0
Hour 60, Days 7 and 30
Query!
Secondary outcome [5]
0
0
Change From Baseline in HAM-D Bech 6 Subscale
Query!
Assessment method [5]
0
0
The HAM-D Bech 6 subscale score is calculated as the sum of the following six items: Item # 1 (depressed mood), Item # 2 (feelings of guilt), Item # 7 (work and activities), Item # 8 (retardation), Item # 10 (anxiety psychic), and Item # 13 (general somatic symptoms). Each item is scored in a range of 0 to 2 or 0 to 4, with higher scores indicating a greater degree of depression. The scores were transformed to a 100-point scale with a higher score indicating a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Query!
Timepoint [5]
0
0
Baseline, Hour 60, Days 7 and 30
Query!
Secondary outcome [6]
0
0
Change From Baseline in HAM-D Individual Item Scores
Query!
Assessment method [6]
0
0
The HAM-D comprises individual ratings of the following symptoms scored in a range of 0 to 2: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following symptoms are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis. Higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.
Query!
Timepoint [6]
0
0
Baseline, Hour 2, Hour 4, Hour 8, Hour 12, Hour 24, Hour 36, Hour 48, Hour 60, Hour 72 and Days 7, 14, 21 and 30
Query!
Secondary outcome [7]
0
0
Change From Baseline at Key Time Points in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
Query!
Assessment method [7]
0
0
The MADRS is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in participants with mood disorders. It was designed as an adjunct to the HAM-D, to be more sensitive than the Hamilton Scale to the changes brought on by antidepressants and other forms of treatment. Each item yielded a score of 0 to 6. The MADRS total score was calculated as the sum of the 10 individual item scores, which ranged from 0 to 60. Higher MADRS scores indicates more severe depression. A negative change from baseline indicates less severe depression. A positive change from baseline indicates more severe depression.
Query!
Timepoint [7]
0
0
Baseline, Hour 60, Days 7 and 30
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) Response
Query!
Assessment method [8]
0
0
The CGI-I item employs a 7-point Likert scale to measure the overall improvement in the participant's condition post-treatment. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions. CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved).
Query!
Timepoint [8]
0
0
Hour 60, Days 7 and 30
Query!
Secondary outcome [9]
0
0
Change From Baseline in the Generalized Anxiety Disorder 7-Item Scale (GAD-7) Total Score
Query!
Assessment method [9]
0
0
The GAD-7 is a participant-rated, generalized anxiety symptom severity scale. Scoring for GAD-7 generalized anxiety is calculated by assigning scores of 0 = "not at all sure," 1 = "several days," 2 = "over half the days," and 3 = "nearly every day" to the response categories. The GAD-7 total score for the seven items ranges from 0 to 21, where a score of 0 to 4 = minimal anxiety, 5 to 9 = mild anxiety, 10 to 14 = moderate anxiety, and 15 to 21 = severe anxiety. The GAD-7 total score was calculated as the sum of the seven individual item scores. A negative change from baseline indicates less anxiety. A positive change from baseline indicates more anxiety.
Query!
Timepoint [9]
0
0
Baseline, Hour 60, Days 7, 14, 21 and 30
Query!
Secondary outcome [10]
0
0
Percentage of Participants With Treatment-Emergent Adverse Events
Query!
Assessment method [10]
0
0
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A treatment-emergent AE (TEAE) is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.
Query!
Timepoint [10]
0
0
Up to approximately 37 days.
Query!
Secondary outcome [11]
0
0
Time to Change in Antidepressant Medication
Query!
Assessment method [11]
0
0
The time to first start or increase in the dose and time to first stop or decrease in the dose of any antidepressant medication.
Query!
Timepoint [11]
0
0
Up to approximately 37 days.
Query!
Eligibility
Key inclusion criteria
Key
- Participants must have ceased lactating at screening; or if still lactating or
actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to
their infant(s) from just prior to receiving study drug through nine days (Day 12)
after the end of the infusion
- Participants had a major depressive episode that began no earlier than the third
trimester and no later than the first 4 weeks following delivery, as diagnosed by
Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I)
- Participant had a HAM-D total score of =26 at screening and Day 1 (prior to dosing)
- Participant was =6 months postpartum at screening
- Participant was amenable to IV therapy
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
45
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Active psychosis
- Attempted suicide associated with index case of postpartum depression
- Medical history of bipolar disorders, schizophrenia, and/or schizoaffective disorder.
Note: Other protocol-defined inclusion/exclusion criteria applied.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
19/10/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
138
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arkansas
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Georgia
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Illinois
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Mississippi
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Jersey
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Texas
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Utah
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sage Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up
to 90 micrograms per kilogram per hour (µg/kg/h) for 60 hours reduces depressive symptoms in
participants with severe postpartum depression (PPD) compared to placebo injection as
assessed by the change from baseline in Hamilton Rating Scale for Depression (HAM-D) total
score.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02942004
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Helen Colquhoun, MD
Query!
Address
0
0
Sage Therapeutics
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02942004
Download to PDF